Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.

A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists from St. Jude Children's Research Hospital and University College London ...

Home Political Cartoons Mr. Moneybags enjoys his health care | May 24 editorial cartoons Saturday's political cartoons feature Medicare and Medicaid cuts, James Comey's social media post, and ...

Discover how hemophilia A affects blood clotting, its genetic patterns, warning signs, advanced treatment options, and lifestyle modifications ...

APRIL marks National Hemophilia Awareness Month in the Philippines. Hemophilia is a medical condition often unseen, yet it is a deeply challenging internal battle for those who live with it.

The FDA has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or hemophilia B.

The approval is based on two randomized clinical trials that enrolled 177 adult and pediatric male patients with either hemophilia A or hemophilia B. Among participants with inhibitors who ...

The FDA has approved fitusiran (Qfitlia), a first-of-its-kind injectable drug to reduce bleeding episodes in people with certain types of hemophilia.

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

For the seventh time in the last three years, the FDA has approved a hemophilia drug, signing off on Sanofi’s fitusiran.

Pfizer has decided to discontinue its hemophilia B gene therapy Beqvez, leaving no active gene therapy program in the company's portfolio.

For centuries, hemophilia was a dangerous genetic disorder with no treatment. Children with hemophilia often didn't make it to adulthood, since a bump or fall could cause massive internal bleeding ...